11 results on '"Bochra Hakim"'
Search Results
2. Chemical alternative for cell identification and cross-contamination detection
- Author
-
Dhouha Msalbi, Jihene Elloumi-Mseddi, Bochra Hakim, Emna Sahli, and Sami Aifa
- Subjects
Original Article ,Environmental Science (miscellaneous) ,Agricultural and Biological Sciences (miscellaneous) ,Biotechnology - Abstract
Misidentification of human cell lines has previously led to confusing results during cell culture experiments. Although several enzymatic as well as molecular analysis approaches have been developed for cell-line authentication, these methods remain costly. In the present paper, we describe a simple chemical alternative based on known compound cell cytotoxicity. In addition to cisplatin, a pool of eight tamoxifen derivative compounds was used to compare the cytotoxic effects on three different breast cancer cell lines: MCF-7, T47D and MDA-MB-231. Our results show that four out of the eight cytotoxic-related compounds allowed to distinguish the different cell lines based on their IC(50) (the half maximal inhibitory concentration) values which are cell type dependent. The remaining chemicals, particularly the most cytotoxic P15, showed close IC(50) values for all the cell lines. Interestingly, flow cytometry experiments have identified notable differences among the three cell lines treated with P15. T47D and MDA-MB231 cells were blocked in SubG1 phase and S phase, respectively, while no significant change in cell cycle profile was noticed for MCF-7 cells. Differences were also noted at the level of caspase-3 activity and cell proliferation in P15-treated cells.
- Published
- 2022
3. Selective cytotoxicity of arene tricarbonylchromium towards tumour cell lines
- Author
-
Sami Mnif, Siden Top, Nejmeddine Akacha, Bochra Hakim, Sami Aifa, Gérard Jaouen, Jihene Elloumi-Mseddi, Pascal Pigeon, Centre de Biotechnologie de Sfax (CBS), Ecole Nationale Supérieure de Chimie de Paris - Chimie ParisTech-PSL (ENSCP), Université Paris sciences et lettres (PSL), Institut Parisien de Chimie Moléculaire (IPCM), Chimie Moléculaire de Paris Centre (FR 2769), Institut de Chimie du CNRS (INC)-École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-Ecole Nationale Supérieure de Chimie de Paris - Chimie ParisTech-PSL (ENSCP), Université Paris sciences et lettres (PSL)-Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI Paris), Université Paris sciences et lettres (PSL)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut de Chimie du CNRS (INC)-École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Chemical Biology (CHEMBIO), and Université Paris sciences et lettres (PSL)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Chimie Moléculaire de Paris Centre (FR 2769)
- Subjects
Tricarbonylchromium ,Inorganic chromium (VI) ,Cytotoxicity ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,[CHIM.THER]Chemical Sciences/Medicinal Chemistry ,010402 general chemistry ,01 natural sciences ,Biochemistry ,Medicinal chemistry ,Inorganic Chemistry ,HeLa ,Materials Chemistry ,Cytotoxic T cell ,[CHIM.COOR]Chemical Sciences/Coordination chemistry ,50% inhibitory concentration ,Physical and Theoretical Chemistry ,Tumour cell lines ,biology ,010405 organic chemistry ,Chemistry ,Organic Chemistry ,HEK 293 cells ,Organometallics ,biology.organism_classification ,0104 chemical sciences ,3. Good health ,Cell culture ,Apoptosis ,Toxicity ,Cancer cell - Abstract
International audience; Metals are cytotoxic and could be harmful to human health; however, as their effects are dose dependant, some of them could be used in chemotherapy. In the present work, mineral chromium (VI) showed that it is cytotoxic on both tumour (MCF-7, HeLa, Hep2 and Caco-2) and non-tumour (HEK293) cell lines. Interestingly, among seven complexes of arene tricarbonylchromium, chromium (0) becomes more efficient in targeting tumour cell lines with less toxicity to non-tumour cells. Three of complexes (formyl benzene tricarbonylchromium 1, anisol tricarbonylchromium 2 and trimethoxy tricarbnylchromium 3) in this study show a decrease of IC50 values for all tested tumour cells compared to the non-tumour cells HEK293. The remaining compounds have an opposite effect; they are less toxic to tumour cells compared to HEK293. The present work demonstrates that some arene tricarbonylchromium are selectively active against cancer cells by inducing apoptosis. The role of aldehyde and methoxyl groups in arene tricarbonylchromium is shown in complexes acquiring the selective tumour cytotoxicity.
- Published
- 2018
- Full Text
- View/download PDF
4. Controversial effect on Erk activation of some cytotoxic drugs in human LOVO colon cancer cells
- Author
-
Jihene Elloumi-Mseddi, Bochra Hakim, Abdelhamid Beji, Sami Aifa, and Ikram Jemel-Oualha
- Subjects
0301 basic medicine ,MAPK/ERK pathway ,Colorectal cancer ,Morpholines ,Blotting, Western ,Apoptosis ,macromolecular substances ,Pharmacology ,Biochemistry ,03 medical and health sciences ,0302 clinical medicine ,Gastrointestinal Agents ,Ciprofloxacin ,Tumor Cells, Cultured ,medicine ,Humans ,Topoisomerase II Inhibitors ,Cytotoxic T cell ,Extracellular Signal-Regulated MAP Kinases ,Cytotoxicity ,Molecular Biology ,Cell Proliferation ,Cell growth ,business.industry ,Kinase ,Trimebutine ,Cell Biology ,biochemical phenomena, metabolism, and nutrition ,medicine.disease ,In vitro ,Enzyme Activation ,030104 developmental biology ,030220 oncology & carcinogenesis ,Colonic Neoplasms ,business - Abstract
The use of some classic antibiotics was recently shown to inhibit growth and to induce apoptosis in human LOVO colon cancer cells. In this study, we describe that ciprofloxacin (CI), trimebutine maleate (COL) and tiemonium methylsulfate (VIS) greatly inhibit cell proliferation in vitro. Proliferation inhibition reached its maximum at 10–4 M, 10–3 M and 10–2 M, respectively, for COL, CI and VIS. Moreover, phospho-extracellular-regulated kinase was totally abrogated in non-apoptotic cytotoxicity of VIS but decreases or increases in the apoptotic inhibition, respectively, of COL and CI treatments.Abbreviations: CI: ciprofloxacin; COL: trimebutine maleate; VIS: tiemonium methylsulfate; MAPK/Erk: mitogen-activated protein kinases/extracellular-regulated kinase
- Published
- 2014
- Full Text
- View/download PDF
5. A novel missense mutation in the ESRRB gene causes DFNB35 hearing loss in a Tunisian family
- Author
-
Melek Mnejja, Mariem Ben Said, Ayda Khalfallah, Zeineb Benzina, Ignacio del Castillo, Khalil Turki, Leila Ayedi, Bochra Hakim, Mounira Hmani Aifa, Abdelmonem Ghorbel, Hammadi Ayadi, Ilhem Charfeddine, Saber Masmoudi, and Chamseddine Khifagi
- Subjects
Adult ,Male ,Models, Molecular ,Tunisia ,Adolescent ,Genetic Linkage ,Hearing loss ,DNA Mutational Analysis ,Molecular Sequence Data ,Mutation, Missense ,Tunisian population ,Genes, Recessive ,Biology ,ESRRB gene ,medicine.disease_cause ,Consanguinity ,Coactivator ,otorhinolaryngologic diseases ,Genetics ,medicine ,Humans ,Missense mutation ,Amino Acid Sequence ,Hearing Loss ,Gene ,Genetics (clinical) ,Mutation ,Chromosome Mapping ,General Medicine ,DNA Fingerprinting ,Molecular biology ,Pedigree ,Receptors, Estrogen ,Genetic Loci ,Case-Control Studies ,Female ,medicine.symptom ,Novel mutation - Abstract
Autosomal recessive non-syndromic hearing loss (ARNSHL) is a genetically heterogenous disorder with 41 genes so far identified. Among these genes, ESRRB whose mutations are responsible for DFNB35 hearing loss in Pakistani and Turkish families. This gene encodes the estrogen-related receptor beta. In this study, we report a novel mutation (p.Y305H) in the ESRRB gene in a Tunisian family with ARNSHL. This mutation was not detected in 100 healthy individuals. Molecular modeling showed that the p.Y305H mutation is likely to alter the conformation of the ligand binding-site by destabilizing the coactivator binding pocket. Interestingly, this ligand-binding domain of the ESRRB protein has been affected in 5 out of 6 mutations causing DFNB35 hearing loss. Using linkage and DHPLC analysis, no more mutations were detected in the ESRRB gene in other 127 Tunisian families with ARNSHL indicating that DFNB35 is most likely to be a rare type of ARNSHL in the Tunisian population.
- Published
- 2011
- Full Text
- View/download PDF
6. DFNB66 and DFNB67 loci are non allelic and rarely contribute to autosomal recessive nonsyndromic hearing loss
- Author
-
Saber Masmoudi, Mounira Hmani-Aifa, Mariem Bensaid, Hammadi Ayadi, B. Hammami, Abdelmonem Ghorbel, Abdelaziz Tlili, Bochra Hakim, Ignacio del Castillo, and Ilhem Charfeddine
- Subjects
Male ,Tunisia ,Hearing Loss, Sensorineural ,DNA Mutational Analysis ,Genes, Recessive ,Locus (genetics) ,Heteroduplex Analysis ,Consanguinity ,Biology ,Frameshift mutation ,Exon ,Genetics ,Humans ,Allele ,Frameshift Mutation ,Gene ,Alleles ,Genetics (clinical) ,Siblings ,Homozygote ,Haplotype ,Chromosome Mapping ,Membrane Proteins ,Exons ,General Medicine ,Introns ,Pedigree ,Haplotypes ,Genetic Loci ,Case-Control Studies ,Microsatellite ,Chromosomes, Human, Pair 6 ,Female ,Microsatellite Repeats - Abstract
We previously mapped the DFNB66 locus to an interval overlapping the DFNB67 region. Mutations in the LHFPL5 gene were identified as a cause of DFNB67 hearing loss (HL). However, screening of the coding exons of LHFPL5 did not reveal any mutation in the DFNB66 family. The objective of this study was to check whether DFNB66 and DFNB67 are distinctive loci and determining their contribution to HL. In the DFNB66 family, sequencing showed absence of mutations in the untranslated regions and the predicted promoter sequence of LHFPL5. Analysis of five microsatellites in the 6p21.31-22.3 region and screening of the LHFPL5 gene by DNA heteroduplex analysis in DHPLC revealed a novel mutation (c.89dup) in one out of 129 unrelated Tunisian families with autosomal recessive nonsyndromic (ARNS) HL. Our findings suggest that two distinct genes are responsible for DFNB66 and DFNB67 HL. These loci are likely to be a rare cause of ARNSHL.
- Published
- 2011
- Full Text
- View/download PDF
7. A novel dominant mutation in SIX1, affecting a highly conserved residue, result in only auditory defects in humans
- Author
-
Saber Masmoudi, J. Mnif, Leila Dhouib, Leila Ayadi, Mohamed Ali Mosrati, Ilhem Charfeddine, B. Hammami, Imen Ben Rebeh, Khaireddine Ben mahfoudh, Abdelmonem Ghorbel, and Bochra Hakim
- Subjects
Adult ,Male ,Models, Molecular ,Protein Conformation ,Molecular Sequence Data ,Sequence alignment ,Locus (genetics) ,Biology ,Kidney ,Conserved sequence ,Genetics ,medicine ,Humans ,Amino Acid Sequence ,Hearing Loss ,Gene ,Peptide sequence ,Conserved Sequence ,Genetics (clinical) ,Homeodomain Proteins ,Branchio-oto-renal syndrome ,Base Sequence ,Genetic heterogeneity ,Ear ,General Medicine ,medicine.disease ,Phenotype ,Pedigree ,Mutation ,Female ,sense organs ,Sequence Alignment ,Branchio-Oto-Renal Syndrome ,Microsatellite Repeats - Abstract
Branchio-oto-renal (BOR) and Branchio-otic (BO) syndromes are dominant disorders characterized by variable hearing impairment (HI) and branchial defects. BOR includes additional kidney malformations. BO/BOR syndromes are genetically heterogeneous and caused by mutations in EYA1 and SIX1 genes. Mutation in SIX1 is responsible also for DFNA23, a locus for non-syndromic HI. Strikingly, the severity of the phenotype did not seem to correlate with the type of SIX1 mutation. Herein, we identified a novel mutation in SIX1 (p.E125K) in a Tunisian family with variable HI and preauricular pits. This mutation is located at the same position as the mutation identified in the Catwhesel (Cwe) mouse. No renal and branchial defects were observed in our family nor in Cwe/+ mice. A homology model revealed that the replacement of the Glutamate by a Lysine alters the electrostatic potential surface propriety which may affect the DNA-binding activity.
- Published
- 2011
- Full Text
- View/download PDF
8. Association of COL1A1 and TGFB1 Polymorphisms with Otosclerosis in a Tunisian Population
- Author
-
Imed Lahmar, Saber Masmoudi, Ilhem Charfeddine, Hassen Hadj-Kacem, Mohamed Ali Mosrati, Malek Mnejja, Guy Van Camp, Ayda Khalfallah, Hammadi Ayadi, Nabil Driss, Leila Dhouib, Isabelle Schrauwen, Abdelmonem Ghorbel, and Bochra Hakim
- Subjects
Genetics ,Case-control study ,Single-nucleotide polymorphism ,Biology ,medicine.disease ,Bone remodeling ,Meta-analysis ,embryonic structures ,Etiology ,medicine ,Otosclerosis ,Sensorineural hearing loss ,Genetics (clinical) ,Genetic association - Abstract
Otosclerosis is a condition characterized by an abnormal bone metabolism in the otic capsule, resulting in conductive and/or sensorineural hearing loss. Otosclerosis is a common disorder in which genes play an important role. Case-control association studies have implicated several genes in the abnormal bone metabolism associated with otosclerosis: COL1A1, TGFB1, BMP2, and BMP4. To investigate the association of these genes with otosclerosis in the Tunisian population, we examined nine single nucleotide polymorphisms (SNPs) in 159 unrelated otosclerosis patients and 155 unrelated controls. We found an association of rs11327935 in COL1A1 with otosclerosis that was shown to be sex specific. The coding polymorphism T263I in TGFB1 was also associated with otosclerosis in the Tunisian population. The effect sizes of both the associations were consistent with previous studies, as the same effect was found in all cases. The association of BMP2 and BMP4 was not significant. However, a trend towards association was found for the BMP4 gene that was consistent with earlier reports. In conclusion, this study replicates and strengthens the evidence for association between polymorphisms of COL1A1 and TGFB1 in the genetic aetiology of otosclerosis.
- Published
- 2011
- Full Text
- View/download PDF
9. Alteration of the serine protease PRSS56 causes angle-closure glaucoma in mice and posterior microphthalmia in humans and mice
- Author
-
Ileana Soto, Danilo G. Macalinao, K. Saidas Nair, I. M. Cosma, Hammadi Ayadi, Peter Söderkvist, Bochra Hakim, Salma Ben Salem, Mounira Hmani-Aifa, Zain Ali, Walid Bouassida, Gareth R. Howell, Alison L. Kearney, Simon W. M. John, Richard S. Smith, and Zeineb Benzina
- Subjects
medicine.medical_specialty ,genetic structures ,Anterior Chamber ,Genetic Linkage ,medicine.medical_treatment ,Eye disease ,Glaucoma ,medicine.disease_cause ,Microphthalmia ,Article ,Retina ,Mice ,Ophthalmology ,Lens, Crystalline ,Genetics ,medicine ,Animals ,Humans ,Microphthalmos ,Eye Abnormalities ,Serine protease ,Mutation ,Protease ,biology ,Anatomy ,medicine.disease ,eye diseases ,Pedigree ,Disease Models, Animal ,medicine.anatomical_structure ,Lens (anatomy) ,biology.protein ,sense organs ,Serine Proteases ,Glaucoma, Angle-Closure - Abstract
Angle-closure glaucoma (ACG) is a subset of glaucoma affecting 16 million people. Although 4 million people are bilaterally blind from ACG, the causative molecular mechanisms of ACG remain to be defined. High intraocular pressure induces glaucoma in ACG. High intraocular pressure traditionally was suggested to result from the iris blocking or closing the angle of the eye, thereby limiting aqueous humor drainage. Eyes from individuals with ACG often have a modestly decreased axial length, shallow anterior chamber and relatively large lens, features that predispose to angle closure. Here we show that genetic alteration of a previously unidentified serine protease (PRSS56) alters axial length and causes a mouse phenotype resembling ACG. Mutations affecting this protease also cause a severe decrease of axial length in individuals with posterior microphthalmia. Together, these data suggest that alterations of this serine protease may contribute to a spectrum of human ocular conditions including reduced ocular size and ACG.
- Published
- 2011
- Full Text
- View/download PDF
10. Effect of estradiol and clomiphene citrate on Erk activation in breast cancer cells
- Author
-
Sami Aifa, Ikram Jemel-Oualha, Bochra Hakim, Abdelhamid Beji, and Jihene Elloumi-Mseddi
- Subjects
MAPK/ERK pathway ,medicine.medical_specialty ,Cell Survival ,MAP Kinase Signaling System ,Apoptosis ,Breast Neoplasms ,Biology ,Biochemistry ,Clomiphene ,Internal medicine ,medicine ,Humans ,Viability assay ,Phosphorylation ,Protein kinase A ,Molecular Biology ,Cell Proliferation ,Mitogen-Activated Protein Kinase 1 ,Mitogen-Activated Protein Kinase 3 ,Estradiol ,Kinase ,Cell growth ,Cell Biology ,Endocrinology ,Cancer research ,MCF-7 Cells ,Female ,Signal transduction - Abstract
The mitogen-activated protein kinase (MAPK) signaling pathway plays key roles in the transmission of proliferative signals in normal and dysregulated cells. Nevertheless, some studies have shown that activation of the extracellular regulated kinases 1/2 (Erk1/2) is involved in apoptosis. In this study, we evaluate the effect of two fertilizing drugs, clomiphene citrate and estradiol, on the activation of Erk1/2 and the viability of two breast cancer cell lines, MCF-7 (hormone dependent) and BT20 (hormone independent).We show that both drugs induce Erk1/2 phosphorylation in MCF-7 and BT20 cells despite their opposite effect on cell viability. In fact, clomiphene citrate is significantly proapoptotic while estradiol promotes cell proliferation. The fact that phospho-Erk1/2 is a common element to both mechanisms suggests that specific factors deciding between proliferation and apoptosis must be operative downstream of this signaling pathway.
- Published
- 2014
11. Association of COL1A1 and TGFB1 polymorphisms with otosclerosis in a Tunisian population
- Author
-
Ayda, Khalfallah, Isabelle, Schrauwen, Malek, Mnejja, Hassen, HadjKacem, Leila, Dhouib, Mohamed Ali, Mosrati, Bochra, Hakim, Imed, Lahmar, Ilhem, Charfeddine, Nabil, Driss, Hammadi, Ayadi, Abdelmonem, Ghorbel, Guy, Van Camp, and Saber, Masmoudi
- Subjects
Adult ,Collagen Type I, alpha 1 Chain ,Male ,Transforming Growth Factor beta1 ,Otosclerosis ,Tunisia ,Humans ,Female ,Middle Aged ,Polymorphism, Single Nucleotide ,Collagen Type I ,Aged - Abstract
Otosclerosis is a condition characterized by an abnormal bone metabolism in the otic capsule, resulting in conductive and/or sensorineural hearing loss. Otosclerosis is a common disorder in which genes play an important role. Case-control association studies have implicated several genes in the abnormal bone metabolism associated with otosclerosis: COL1A1, TGFB1, BMP2, and BMP4. To investigate the association of these genes with otosclerosis in the Tunisian population, we examined nine single nucleotide polymorphisms (SNPs) in 159 unrelated otosclerosis patients and 155 unrelated controls. We found an association of rs11327935 in COL1A1 with otosclerosis that was shown to be sex specific. The coding polymorphism T263I in TGFB1 was also associated with otosclerosis in the Tunisian population. The effect sizes of both the associations were consistent with previous studies, as the same effect was found in all cases. The association of BMP2 and BMP4 was not significant. However, a trend towards association was found for the BMP4 gene that was consistent with earlier reports. In conclusion, this study replicates and strengthens the evidence for association between polymorphisms of COL1A1 and TGFB1 in the genetic aetiology of otosclerosis.
- Published
- 2011
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.